Intuitive Surgical (ISRG) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Intuitive Surgical is sailing against a few new headwinds. So far its financial performance hasn't been severely impacted.
Intuitive Surgical's da Vinci robots help doctors perform surgeries with fewer errors. Procedure growth is impressive, driving revenue for the company's instruments and accessories.
Intuitive Surgical (ISRG) is making strides in the robotic-assisted surgery market with its existing and new launches. However, macro challenges are likely to continue to hurt its performance.
Robotic surgery conjures up futuristic images of automated machines performing surgery on anesthetized human patients in an assembly line, but that's not the case at the moment. Robots have yet to replace human surgeons.
Johnson & Johnson hasn't performed that well in the past decade. By contrast, Vertex Pharmaceuticals and Intuitive Surgical have been exceptional.
Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.
If you are looking for AI-related stocks you can buy and hold forever, look no further than this list. The stocks on this list are applying AI, and the application of AI counts.
As I'm sure everyone reading this is aware, artificial intelligence, or AI, has been quite a volatile sector in the recent past. All indicators suggest this will continue in the near to semi-long-term future.
Intuitive Surgical has an impressive international growth opportunity with hospitals. Growth and valuation expansion have combined to fuel investment returns.
Intuitive Surgical's procedure volume in one key category is declining. However, the medical device specialist continues to record excellent financial results.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?